H.C. Wainwright Trims Bionano Genomics Price Target While Maintaining Buy Rating

Key Facts

1H.C. Wainwright lowered the price target for Bionano Genomics (BNGO) from $7 to $6.

2The price target adjustment is primarily due to an increased share count (dilution).

3The firm maintained a 'Buy' rating, with management guidance suggesting up to 16% revenue growth in 2026.

H.C. Wainwright has adjusted its price target for Bionano Genomics (BNGO) downward, moving from $7 to $6 per share. The revision is primarily attributed to an increased share count, which has resulted in dilution for existing shareholders. Despite the lower price target, the investment firm maintained its 'Buy' rating on the stock, signaling long-term optimism. While the company faces revenue headwinds in 2025, management guidance points toward a significant recovery with 16% growth projected for 2026. This mixed outlook balances immediate concerns over share dilution against the company's potential for future expansion in the biotech sector. Investors are closely watching BNGO as it navigates these fiscal adjustments and works toward its 2026 revenue targets.